Fig. 6From: Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levelsComparison of rates of severe adverse events between rituximab and cyclophosphamide groups in IMN patientsBack to article page